

## INDEX

### A

- Abdomen
  - imaging, *Mar. 52*
  - pain, *Oct. 18*
- Acetaminophen, *Feb. 65*
- Acromegaly: in
  - hyperprolactinemia etiology, *June 20*
- ACTH: and opioids, *July 43*
- Acupuncture: and opioids, *July 28-29*
- Addiction, drug, *Jan. 42*
- opioids and, *July 32-33*
- Adenocarcinoma: after asbestos exposure, *Sept. 22*
- Adenoma, multiple endocrine (see MEA)
- Adenopathy, retroperitoneal, *Mar. 51-54*
  - diagnostic approach, *Mar. 53*
- Adenoviral infections, *May 41*
- Adrenal mass, *Mar. 57*
  - diagnostic approach, *Mar. 59*
- Age-related incidence: of bacterial arthritis, *Jan. 27*
- Aged: renal tubular necrosis of, *Feb. 49-50*
- Aging: radiation-induced, *Mar. 39-40*
- Agranulocytosis, *Jan. 43*
- Albuminuria: in nephrotic syndrome, pathogenesis, *Feb. 71-73*
- Alcohol
  - dependence, and opioids, *July 33*
  - peptic ulcer and, *Dec. 16*
- Amenorrhea, *June 11-12*
  - evaluation of, *June 26-32*
  - hyperprolactinemia and, *June 10*
  - radiography of, *June 27-30*
  - treatment, *June 32-33*
- Aminoglycosides
  - concentrations, therapeutic and toxic, *Feb. 31*
  - kidney failure due to, *Feb. 26-35*
  - nephrotoxicity, risk factors in, *Feb. 29*
- Amphetamine-associated nephropathy, *Feb. 70*
- Amphotericin B: causing kidney failure, *Feb. 37-39*
- Amyloidosis: causing nephrotic syndrome, *Apr. 24-27*
- Analgesia: experimental manipulation effects on, *July 26*
- Analgesic
  - associated nephropathy, *Feb. 62*
  - compounds, common, *Feb. 65*
- Aneurysm, aortic, abdominal, *Mar. 54-55*
  - diagnostic approach, *Mar. 54*
- Angiography, *Mar. 27-28*
- Antacids: potency of, *Dec. 42-43*
- Antibiotics
  - in arthritis, infectious, choice, duration and route, *Jan. 35*
  - kidney failure due to, *Feb. 26-40*
  - diagnosis, *Feb. 28-33*
  - treatment, *Feb. 28-33*
- Anticonvulsants: and nephrotic syndrome, *Feb. 78*
- Antigens: microbial, in synovial fluid, *Jan. 47-48*
- Antrum: lesser curve of, ulcer on, *Dec. 35*
- Aortic aneurysm, abdominal, *Mar. 54-55*
  - diagnostic approach, *Mar. 54*
- Apexcardiography: in cardiomyopathy, *Nov. 25*
- APUD system, *Aug. 30-33*
- Arboviruses, *Jan. 29*

Arteries  
  coronary (see Coronary arteries)  
  femoral, pressure recordings from, *Nov.* 38  
Arteriosclerosis: accelerated, and proteinuria, *Apr.* 16-17  
Arthritis, *Oct.* 18  
  bacterial, *Jan.* 26-28  
    incidence of, age-related, *Jan.* 27  
  bypass, *Escherichia coli* in, *Jan.* 48  
  fungal, *Jan.* 29-30  
  infectious, *Jan.* 6-51  
    anatomy of infection, *Jan.* 6-20  
    antibiotics in, choice, duration and route, *Jan.* 35  
    arthroscopy in, *Jan.* 26  
    biopsy in, *Jan.* 22-24  
    biopsy in, needle, *Jan.* 26  
    bone scan in, *Jan.* 25-26  
    CT in, *Jan.* 25-26  
    cultures in, *Jan.* 22-24  
    diagnostic tests in, *Jan.* 20-26  
    history in, *Jan.* 20-21  
    laboratory investigations in, routine, *Jan.* 21-22  
    organisms in, *Jan.* 26-34  
    physical examination in, *Jan.* 20-21  
    preexisting arthritis and, *Jan.* 41-42  
    prognostic factors in, *Jan.* 36-37  
    radiography in, *Jan.* 24-25  
    special host and, *Jan.* 41-43  
    treatment considerations, special, *Jan.* 35-41  
  after intestinal bypass, *Jan.* 40  
  Lyme, *Jan.* 33-34, 47  
  postmeningococcal, *Jan.* 39-40  
  poststaphylococcal, *Jan.* 39-40  
  "reactive," *Jan.* 37  
  rheumatoid, *Oct.* 32-34  
    infection in, *Jan.* 47-48  
  syphilitic, *Jan.* 34  
  viral, *Jan.* 28-29

Arthroscopy: in infectious arthritis, *Jan.* 26  
Asbestos, *Sept.* 7-37  
  body in sputum, *Sept.* 13  
  carcinogenic effect of, *Sept.* 21  
  exposure  
    adenocarcinoma after, *Sept.* 22  
    lung carcinoma and, *Sept.* 22  
    mesothelioma and, malignant, *Sept.* 22-24  
    occupations with, *Sept.* 9-10  
    smoking and, *Sept.* 22  
  lung parenchyma fibrogenic response to, *Sept.* 11  
  minerals, *Sept.* 8-9  
  amphiboles, *Sept.* 9  
  serpentine, *Sept.* 9  
  types of, *Sept.* 8-9  
Asbestosis  
  case review in, *Sept.* 25-37  
  crow's feet in, *Sept.* 32-33  
  diagnosis, criteria for, *Sept.* 18-19  
  differentiation of, *Sept.* 17  
  early changes in, *Sept.* 17  
  emphysema and, *Sept.* 35  
  lung function changes in, *Sept.* 34  
  pathologic feature of, *Sept.* 16  
  plaque in, calcified, *Sept.* 26-27  
  pleura in  
    calcification, *Sept.* 31  
    calcification, linear, *Sept.* 28-29  
    effusions, *Sept.* 14-15, 38  
    plaques, *Sept.* 11-13  
    plaques, calcified, *Sept.* 29  
    thickening, *Sept.* 32-33  
    symptoms of, clinical, *Sept.* 16  
Aspiring, *Feb.* 65

## B

Bacteremia: streptococcal, and naloxone, *July* 35  
Bacteremic tenosynovitis, *Jan.* 12-13  
Bacterial arthritis, *Jan.* 26-28

incidence of, age-related, *Jan.* 27  
 Barium enema, *Mar.* 65-66  
 Beat phenomenon:  
   postextrasystolic, *Nov.* 41  
 Behavior: and opioids, *July* 29-32  
 Beta-endorphin: (in rat), *July* 30  
 Biopsy  
   in arthritis, infectious, *Jan.*  
     22-24  
     needle, *Jan.* 26  
   immunofluorescent, in immune  
     complex disease, *Oct.* 17  
   lung, in silicosis, *Sept.* 42  
 Blastomycosis: North American,  
   *Jan.* 30  
 Blood  
   -borne dissemination of viral  
     exanthems, *May* 12-13  
   pressure  
     naloxone and, *July* 35  
     opioids and, *July* 34-36  
 Bone scanning: in infectious  
   arthritis, *Jan.* 25-26  
 Brain: opioids in, *July* 13-14  
 Breast: prolactin action on, *June*  
   24-26  
 Bromocriptine  
   pregnancy after, *June* 41  
   in prolactinoma, in women, *June*  
     35-43  
 Bureau of Radiological Health,  
   *Mar.* 79  
 Bursitis, *Jan.* 13-14  
   septic, *Jan.* 13-14  
 Bypass  
   arthritis, *Escherichia coli* in,  
     *Jan.* 48  
   intestinal, arthritis after, *Jan.*  
     40

## C

Calcific tendinitis, *Jan.* 43-44  
 Calcification  
   of lymph node in silicosis, *Sept.*  
     49  
   of pleura in asbestosis, *Sept.* 31  
   linear, *Sept.* 28-29

Calcified plaque in asbestosis,  
   *Sept.* 26-27  
   pleural, *Sept.* 28-29  
 Calcitonin, *Aug.* 17  
 Cancer  
   induction and radiation, *Mar.*  
     41-47  
   nephrotic syndrome due to, *Apr.*  
     27-29  
 Captopril: and nephrotic  
   syndrome, *Feb.* 78  
 Carcinogenesis: risk after  
   radiation, *Mar.* 36  
 Carcinogenic  
   effect of asbestosis, *Sept.* 21  
   induction by radiation, *Mar.*  
     42-43  
 Carcinoma  
   adenocarcinoma after asbestos  
     exposure, *Sept.* 22  
   lung, and asbestos exposure,  
     *Sept.* 22  
   thyroid, medullary, *Aug.*  
     8-37  
     clinical presentation, *Aug.*  
       9-10  
     comparison of sporadic and  
       familial, *Aug.* 8  
     diagnosis, *Aug.* 10-12  
     endocrine abnormalities in,  
       *Aug.* 20-28  
     glossary for, *Aug.* 3-4  
     hyperparathyroidism and,  
       *Aug.* 22-28  
     pathogenesis theories, *Aug.*  
       29-30  
     pathology, *Aug.* 10  
     pheochromocytoma and, *Aug.*  
       20-22  
     treatment, *Aug.* 12-14  
 Cardiac (*see* Heart)  
 Cardiomyopathy, coronary arteries  
   in (*see* Coronary arteries in  
     cardiomyopathy)  
 Cardiomyopathy, hypertrophic,  
   *Nov.* 7-78  
   abnormalities in, distribution of,  
     *Nov.* 19-20

- Cardiomyopathy (*cont.*)  
 anatomical findings in, gross,  
   Nov. 15  
 apexcardiography in, Nov. 25  
 carotid pulse tracings in, Nov.  
   25  
 cineangiographic abnormalities  
   in, Nov. 32-26  
 diagnostic features, Nov. 60-62  
 echocardiography in, Nov. 44-50  
   M-mode, Nov. 44-50  
   two-dimensional, Nov. 50-54  
 electrocardiography in, Nov.  
   29-32  
   monitoring, ambulatory, Nov.  
   31-32  
   scalar, Nov. 29-31  
 etiology, Nov. 57-60  
 hemodynamic findings, Nov.  
   36-44  
 historical perspectives, Nov.  
   8-12  
 microscopic findings in, Nov.  
   18-19  
 murmur in, Nov. 28  
 natural history, Nov. 62-67  
 nomenclature in, Nov. 12-13  
 pathology, Nov. 13-20  
   gross features, Nov. 13-19  
 phonocardiography in, Nov. 25  
 physical examination in, Nov.  
   23-29  
 radiography in, Nov. 32-36  
   chest, Nov. 32  
 scanning  
   heart, Nov. 54-57  
   myocardial with  $^{201}\text{Tl}$ , Nov. 55  
 sudden death in, predictors of,  
   Nov. 65  
 symptoms, Nov. 20-23  
 treatment  
   medical, Nov. 67-76  
   surgical, Nov. 75-77  
 Carotid pulse tracings: in  
   cardiomyopathy, Nov. 25  
 Cataracts: and radiation, Mar.  
   40-41  
 C-cell  
   hyperplasia, Aug. 14-17  
   parafollicular, Aug. 18-20  
 Cell(s)  
   C-cell (*see* C-cell)  
   sickle, Jan. 42  
 Cephalalexin: causing purpura, Oct.  
   18  
 Cephalosporins: causing kidney  
   failure, Feb. 35-37  
 Cerebrospinal fluid: opioids in,  
   July 19  
 Chest radiography: in  
   cardiomyopathy, Nov. 32  
 Chicken pox, May 24-25  
 Chikungunya virus, May 43-44  
 Chlamydia, Jan. 39  
 Chlorpheniramine: structure, Dec.  
   38  
 Cholecystitis: diagnostic approach,  
   Mar. 65, 66  
 Cholelithiasis: diagnostic  
   approach, Mar. 66  
 Cigarette smoking (*see* Smoking)  
 Cimetidine  
   side effects of, Dec. 39  
   structure of, Dec. 38  
   ulcer remission during, Dec. 45  
 Cineangiographic abnormalities:  
   in cardiomyopathy, Nov.  
   32-26  
 Cis-platinum: causing kidney  
   failure, Feb. 40-43  
 Coccidioidomycosis, Jan. 29-30  
 Collagen vascular disease  
   asbestosis and, Sept. 17  
   silicosis and, Sept. 43  
 Colorado tick fever virus, May 43  
 Computed (*see* Tomography,  
   computed)  
 Congenital effects: of radiation (in  
   mammals), Mar. 46  
 Coronary arteries in  
   cardiomyopathy  
   epicardial, Nov. 15  
   intramural, Nov. 15  
 Corticosteroids: in vasculitis,  
   indications for, Oct. 44  
 Coxsackievirus  
   A2, May 30  
   A4, May 30-31

A5, *May* 31  
A7, *May* 31  
A9, *May* 31-34  
A10, *May* 34  
A16, *May* 34-36  
B1, *May* 36  
B2, *May* 36  
B3, *May* 36  
B4, *May* 37  
B5, *May* 37

C-reactive protein: in SLE, *Jan.* 49  
Crow's feet: in asbestosis, *Sept.*  
32-33

Cryoglobulin, *Oct.* 26

Cryoglobulinemia

essential, *Oct.* 27-28

mixed, *Oct.* 27-28

diseases associated with, *Oct.*  
27

Cryptococcosis, *Jan.* 30

Crystal deposition disease, *Jan.* 45

Cutaneous (*see* Skin)

Cytology: sputum, and smoking  
with asbestos exposure,  
*Sept.* 22

Cytomegalovirus, *May* 45

## D

Death: sudden, in cardiomyopathy,  
predictors of, *Nov.* 65

Dengue virus, *May* 44

Dermatomyositis-polymyositis,  
*Oct.* 34

Diabetes mellitus: causing  
nephrotic syndrome, *Apr.*  
22-24

Diet: and peptic ulcer, *Dec.* 14-15

Digital infarction: in rheumatoid  
vasculitis, *Oct.* 33

Disk space infection:  
intervertebral, *Jan.* 17-18

Dose (*see* Radiation, dose)

Drainage: of septic joint, *Jan.* 36

Drug(s)

addiction, *Jan.* 42

in hyperprolactinemia etiology,  
*June* 16-19

-induced

glomerulonephritis, *Feb.*

69-70

kidney failure, chronic, *Feb.*

59-61

nephrotic syndrome, *Feb.*

70-78

nephrotoxic renal failure,

etiology, *Feb.* 26-47

nephrotoxic syndrome,

pathogenesis, *Feb.* 74-76

nephrotoxicity, *Feb.* 8-81

nephrotoxicity, etiology, *Feb.* 9

tubulointerstitial disease (*see*

Tubulointerstitial disease,  
drug-induced)

in nephritis, interstitial, *Feb.* 51

nephrotic syndrome and, *Apr.*

33-36

ulcer and, peptic, *Dec.* 17-19,

37-43

Duodenal (*see* Ulcer, duodenal)

Dysenteries, *Jan.* 38

## E

Echocardiography in

cardiomyopathy, *Nov.* 44-50

M-mode, *Nov.* 44-50

two-dimensional, *Nov.* 50-54

Echovirus

9, infection, signs and symptoms  
in, *May* 39

1 through 33, *May* 37-41

Economics: of peptic ulcer, *Dec.*

8-11

Edema

mechanisms in nephrotic

syndrome, *Apr.* 11

proteinuria and, *Apr.* 10-13

Elderly: renal tubular necrosis of,  
*Feb.* 49-50

Electrocardiography (*see*

Cardiomyopathy,

hypertrophic,

electrocardiography in)

Electron

micrograph

- Electron (*cont.*)  
of glomerulonephritis, *Feb. 75*  
of nephropathy, minimal-  
change, *Apr. 40*  
photomicrograph of normal  
glomerulus, *Apr. 40*
- Embryology: of thyroid, *Aug.*  
29-30
- Emotional factors: in peptic ulcer,  
*Dec. 21-24*
- Emphysema: in asbestosis, *Sept.*  
35
- Endocrine  
abnormalities in thyroid  
carcinoma, medullary, *Aug.*  
20-28  
adenoma, multiple (*see* MEA)  
evaluation in  
hyperprolactinemia, *June*  
30-32
- Endorphins, *July 3-53*  
chemistry of, *July 6-7*  
concentrations in plasma, *July*  
17-19  
structure of, *July 5*  
terminology for, *July 4*
- $\beta$ -Endorphin: (in rat), *July 30*
- Endoscopy: in peptic ulcer, *Dec.*  
31-36
- Enema: barium, *Mar. 65-66*
- Enkephalins, *July 3-53*  
chemistry of, *July 8-9*  
concentrations in plasma, *July*  
17-19  
structure of, *July 5*  
terminology for, *July 4-6*
- Enteroviruses, *May 30-41*  
infections due to, characteristics  
of cutaneous findings in,  
*May 32-33*  
71, *May 41*
- Environmental  
factors in peptic ulcer, *Dec. 19*  
protection and radiation, *Mar.*  
88
- Epstein-Barr virus, *May 45*
- Erythema  
elevatum diutinum, *Oct. 28-30*  
infectiosum, *May 48-49*  
multiforme, *May 18*  
nodosum, *Jan. 19-20*
- Erythematous (*see* Exanthems,  
erythematous)
- Escherichia coli*: in bypass  
arthritis, *Jan. 48*
- Examination: physical, in  
cardiomyopathy, *Nov.*  
23-29
- Exanthem(s)  
with distinctive clinical features,  
*May 18-19*  
erythematous  
macular, *May 15*  
maculopapular, *May 15-16*  
meningitis and, *May 19*  
nodular, *May 18*  
papular, *May 18*  
petechial, *May 17*  
pulmonary involvement and,  
*May 19*  
purpuric, *May 17*  
subitum, *May 46-48*  
in syndromes, *May 18-19*  
types of, *May 15-18*  
ulcerative, *May 18*  
urticarial, *May 17-18*  
vesicular, *May 16-17*  
viral, *May 6-56*  
associated with cutaneous  
manifestations, *May 7-11*  
blood-borne disseminations,  
*May 12-13*  
classic, *May 19-25*  
diagnosis, *May 49-53*  
diagnosis, clinical, approach  
to, *May 49-52*  
diagnosis, differential, *May*  
49-53  
diagnosis, laboratory, *May*  
52-53  
diagnosis, methods for, most  
useful, *May 53*  
history of, *May 7*  
manifestations, clinical, *May*  
14-19  
pathogenesis of, *May 11-14*  
respiratory, importance of,  
*May 42-43*
- Exercise: and opioids, *July*  
33-34

## F

- Feeding: and opioids, *July* 37-39
- Femoral artery: pressure recordings from, *Nov.* 38
- Fertility: and radiation, *Mar.* 40, 76
- Fetus: and radiation, *Mar.* 44-47, 75
- Fever: rheumatic, *Jan.* 40-41
- Fibrocartilaginous joint: infection, *Jan.* 9
- Fibrosis
  - lung (*see* Lung, fibrosis)
  - myocardial, in ventricular septum, *Nov.* 16
- Fifth disease, *May* 48-49
- Fluid
  - joint, *Jan.* 22
  - in rheumatic disease, *Jan.* 23
  - synovial, microbial antigen in, *Jan.* 47-48
- Fluoroscopic
  - examination, *Mar.* 24-26
  - procedures, reported dose from, *Mar.* 27
- Fracture: and rheumatic disease, *Jan.* 44
- Fungal arthritis, *Jan.* 29-30

## G

- Galactorrhea, *June* 9-11
  - evaluation of, *June* 26-32
  - hyperprolactinemia and, *June* 10
  - nonhyperprolactinemic, treatment of, *June* 44-45
  - radiography of, *June* 27-30
  - treatment, *June* 32-33, 44-45
- Gallbladder
  - disease, *Mar.* 67
  - imaging of, *Mar.* 61-62
- Gastric (*see* Stomach)
- Gastrointestinal
  - function abnormalities in duodenal ulcer, *Dec.* 24-28
  - hemorrhage, upper, in ulcer, *Dec.* 48-50

- Generators
  - ultrasonic, *Mar.* 10-11
  - x-ray, *Mar.* 7-8
- Genetic
  - effects of radiation, *Mar.* 47-50
  - syndromes, with peptic ulcer, *Dec.* 12-13
- Genetically significant dose, *Mar.* 20, 74
  - sources of, *Mar.* 48
- German measles, *May* 22-24
- Glomerular filtration barrier, *Feb.* 72
- Glomerulonephritis, *Oct.* 18
  - drug-induced, *Feb.* 69-70
  - membranoproliferative, and nephrotic syndrome, *Apr.* 46-49
  - membranous
    - electron micrograph of, *Feb.* 75
    - gold and, *Feb.* 77
- Glomerulopathy: membranous, *Apr.* 36-39
- Glomerulosclerosis: focal, and nephrotic syndrome, *Apr.* 43-46
- Glomerulus
  - contributions in nephrotic syndrome, *Apr.* 7-8
  - defect, *Apr.* 8-9
  - normal, electron photomicrograph of, *Apr.* 40
  - pore size and charge, *Apr.* 8-9
- Gold: and glomerulonephritis, *Feb.* 77
- Gonadal
  - dose of radiation, *Mar.* 74
  - hypothalamic-pituitary axis and prolactin, *June* 24-26
- Gonadotropins: and opioids, *July* 41-42
- Gonorrhea: experimental models for, *Jan.* 49
- Granulomatosis: Wegener's, *Oct.* 36-37
- Granulomatous vasculitis, *Oct.* 34-37

## H

- Hand-foot and mouth syndrome,  
*May 18-19*  
 (See also Coxsackievirus A5, A9,  
 A10, B1 and B3)  
 signs in, *May 35*  
 symptoms in, *May 35*
- Heart  
 output, and naloxone, *July 35*  
 rate, and naloxone, *July 35*  
 scanning in cardiomyopathy,  
*Nov. 54-57*
- Hemarthrosis, *Jan. 44*
- Hemoglobinopathy, *Jan. 42*
- Hemorrhage: gastrointestinal,  
 upper, in ulcer, *Dec. 48-50*
- Henoch-Schönlein purpura, *Oct.*  
*18, 20-23*
- Hepatitis B, *Jan. 28, May 46*
- Heroin-associated nephropathy,  
*Feb. 69-70*
- Hip synovitis: transient, *Jan. 41*
- Histamine: structure, *Dec. 38*
- Histoplasmosis, *Jan. 30*
- HLA B27: disease associated with,  
*Jan. 37*
- Hormone(s)  
 pituitary, secretion, and opioids,  
*July 39-45*  
 vasoconstrictor, *Feb. 12*  
 vasodilator, *Feb. 12*
- Hospitalizations: for ulcer, *Dec. 10*
- Host: special, and infectious  
 arthritis, *Jan. 41-43*
- Hypercoagulability: in nephrotic  
 syndrome, possible  
 mechanisms, *Apr. 19*
- Hyperlipidemia: and proteinuria,  
*Apr. 14-15*
- Hyperparathyroidism: and thyroid  
 carcinoma, *Aug. 22-28*
- Hyperplasia: C-cell, *Aug. 14-17*
- Hyperprolactinemia, *June 6-58*  
 abbreviations used, *June 6-7*  
 amenorrhea and, *June 10*  
 etiology, *June 16-23*  
 acromegaly in, *June 20*  
 drugs in, *June 16-19*

- hypothalamic disease in, *June*  
*20*
- metabolic disturbances in,  
*June 19*
- neurogenic, *June 16*
- prolactinoma in, *June 20-23*
- pseudocyesis in, *June 20*
- evaluation of, *June 26-32*
- endocrine, *June 30-32*
- galactorrhea and, *June 10*
- idiopathic, treatment, *June*  
*32-33*
- infertility and, *June 10*
- manifestations of, *June 9-13*
- physiologic, *June 7-8*
- radiography of, *June 27-30*
- therapeutic questions remaining  
 unanswered, *June 46-47*  
 treatment, *June 32-45*
- Hypertrophic (see Cardiomyopathy,  
 hypertrophic)
- Hypoalbuminemia: and  
 proteinuria, *Apr. 9-10*
- Hypocomplementemic vasculitis,  
*Oct. 23-27*
- Hypoglycemia: insulin-induced,  
*July 18*
- Hypotension: and naloxone, *July*  
*35*
- Hypothalamic  
 disease in hyperprolactinemia  
 etiology, *June 20*  
 -pituitary axis, activation of,  
*July 18*  
 -pituitary-gonadal axis and  
 prolactin, *June 24-26*

## I

- Imaging (see Scanning)
- Immune complex  
 disease, immunofluorescent  
 biopsy in, *Oct. 17*  
 formation in situ, *Feb. 76*
- Immunofluorescent biopsy: in  
 immune complex disease,  
*Oct. 17*
- Impotence, *June 13*

Infarction: digital, in rheumatoid vasculitis, *Oct. 33*

**Infection**

anatomy of, *Jan. 6-20*

in arthritis (*see* Arthritis, infectious)

closed-space, *Jan. 14-15*

intervertebral disk space, *Jan. 17-18*

joint, *Jan. 7-12*

fibrocartilaginous, *Jan. 9*

prosthetic, *Jan. 9-12*

synovial, *Jan. 8-9*

microbial, *Jan. 18*

muscle, *Jan. 15-16*

mycobacterial, *Jan. 18-19*

of rheumatic disease, chronic, and disguise, *Jan. 45-47*

rheumatic disease problems misdiagnosed as, *Jan. 43-45*  
in rheumatoid arthritis, *Jan. 47-48*

"rheumatologic" cutaneous signs of, *Jan. 19-20*

systemic, *Jan. 18-19*

systemic signs of, *Jan. 19-20*

tenosynovium, *Jan. 12*

focal, *Jan. 12*

venereal, *Jan. 39*

viral, *Jan. 18*

Infertility, *June 12-13*

hyperprolactinemia and, *June 10*

Influenza A and B viruses, *May 42*

Insulin-induced hypoglycemia, *July 18*

Intervertebral sick: space infection, *Jan. 17-18*

**Intestine**

(*See also* Gastrointestinal)

bypass, arthritis after, *Jan. 40*

Irradiation (*see* Radiation)

Ischemic renal failure: pathogenic pathways in, *Feb. 19*

**J**

Jaundice, obstructive, *Mar. 60-61*

diagnostic approach, *Mar. 64*

**Joint**

fluid, *Jan. 22*

in rheumatic disease, *Jan. 23*

infection (*see* Infection, joint)

septic, drainage of, *Jan. 36*

**K**

Keflex: causing purpura, *Oct. 18*

**Kidney**

excretion of proteins, *Apr. 7*

failure, acute, *Feb. 8-58*

aminoglycosides causing, *Feb. 26-35*

amphotericin B causing, *Feb. 37-39*

antibiotics causing (*see* Antibiotics, kidney failure due to)

cephalosporins causing, *Feb. 35-37*

cis-platinum causing, *Feb. 40-43*

drug-induced nephrotoxic, etiology, *Feb. 26-47*

metals causing, heavy, *Feb. 40-43*

methotrexate and, *Feb. 56-57*

methoxyflurane causing, *Feb. 46-47*

methysergide and, *Feb. 58*

pathogenic pathways in, *Feb. 19*

polymyxins causing, *Feb. 39-40*

prerenal, *Feb. 10-16*

prerenal, diagnosis, differential, *Feb. 13-15*

prerenal, pathophysiology, *Feb. 10-13*

prerenal, treatment, *Feb. 15-16*

radiocontrast agents causing, *Feb. 43-46*

secondary to intrarenal processes, *Feb. 16-17*

secondary to obstructive causes, *Feb. 55-58*

sulfonamides and, *Feb. 57*

**Kidney (cont.)**

- tetracyclines causing, *Feb.* 39-40
- urinary indices in, *Feb.* 25
- failure, chronic, *Feb.* 59-70
- drug-induced, *Feb.* 59-61
- failure and nephrotic syndrome, *Apr.* 17
- histopathology resembling idiopathic nephrotic syndrome, *Apr.* 21
- mass *Mar.* 55, 56, 57
- diagnostic approach to, *Mar.* 56
- nonfunctioning, *Mar.* 55-56
- diagnostic approach, *Mar.* 58
- papillary necrosis, *Feb.* 66
- tubular necrosis, acute in aged, *Feb.* 49-50
- clinical course, *Feb.* 23-24
- definition, *Feb.* 17-26
- diagnosis, *Feb.* 24-26
- morphologic alterations in, early, *Feb.* 21
- pathology, *Feb.* 17-23
- pathophysiology, *Feb.* 17-23
- preexisting renal disease in, *Feb.* 48
- treatment, *Feb.* 47-50
- volume depletion in, *Feb.* 48-49
- tubule, contributions in nephrotic syndrome, *Apr.* 7-8
- tubulointerstitial disease (see Tubulointerstitial disease)
- Klebsiella pneumoniae*, *Jan.* 38-39
- Kunjin virus, *May* 44

**L**

- Lassa virus, *May* 44
- Leprosy, *Jan.* 32-33
- Leukocytoclastic vasculitis, *Oct.* 14, 16, 19-30, *Jan.* 20

systemic diseases associated with, *Oct.* 21

Life expectancy: loss of, causes of, *Mar.* 15

Lipiduria: and proteinuria, *Apr.* 14-15

Lithium-associated nephropathy, *Feb.* 68-69

Livedo reticularis, *Oct.* 38

**Liver**

imaging, *Mar.* 58-59

mass, focal, *Mar.* 63

diagnostic approach, *Mar.* 62

Local governments: and radiation, *Mar.* 82

**Lung**

biopsy in silicosis, *Sept.* 42

carcinoma, and asbestos exposure, *Sept.* 22

**fibrosis**

interstitial, diffuse, *Sept.* 15

interstitial, diffuse, in asbestosis, *Sept.* 35

lung function tests in, *Sept.* 17

pathogenesis of, *Sept.* 15-16

physical examination in, *Sept.* 16-17

**function**

changes in asbestosis, *Sept.* 34

tests in fibrosis, *Sept.* 17

tests, serial, *Sept.* 20

insufficiency in silicosis, *Sept.* 43

involvement, and exanthem, *May* 19

parenchyma, fibrogenic response to asbestos, *Sept.* 11

**Lupus**

erythematosus, systemic, *Oct.* 30-31

CRP in, *Jan.* 49

nephrotic syndrome due to, *Apr.* 29-33

nephritis, clinical features of, *Apr.* 31

Lyme arthritis, *Jan.* 33-34, 47

Lymph node: calcification in silicosis, *Sept.* 49

## M

- Macular exanthems:
  - erythematous, *May 15*
- Malignancy (see Cancer)
- Mammography, *Mar. 24, 66-68*
- Marburg virus, *May 45*
- MEA, *Aug. 22-30*
  - glossary for, *Aug. 3-4*
  - I syndrome, *Aug. 26-28*
  - organ system involvement in, *Aug. 24*
  - II syndrome
    - characterization of, *Aug. 23-26*
    - pathogenesis theories, *Aug. 29-30*
- Measles, *May 19-22*
  - atypical, *May 27-28*
  - German, *May 22-24*
  - mild modified, *May 26-27*
  - typical, in adults, *May 26*
  - in vaccine era, *May 25-28*
- Meningitis
  - exanthem and, *May 19*
  - naloxone and, *July 35*
- Mesothelioma: malignant, and asbestos exposure, *Sept. 22-24*
- Metals: heavy, causing kidney failure, *Feb. 40-43*
- Methotrexate: and kidney failure, *Feb. 56-57*
- Methoxyflurane: causing kidney failure, *Feb. 46-47*
- Methysergide: and kidney failure, *Feb. 58*
- Microadenoma: CT of, *June 29*
- Microbial
  - antigen, in synovial fluid, *Jan. 47-48*
  - infection, *Jan. 18*
- Micrograph (see Electron, micrograph)
- Microscopy: in hypertrophic cardiomyopathy, *Nov. 18-19*
- Minerals (see Asbestos, minerals)
- M-mode echocardiography: in cardiomyopathy, *Nov. 44-50*

- Models: experimental, for gonorrhea, *Jan. 49*
- Monitoring: ECG, in cardiomyopathy, *Nov. 31-32*
- Mumps virus, *May 46*
- Murmur: in cardiomyopathy, *Nov. 28*
- Muscle infection, *Jan. 15-16*
- Mycobacteria, *Jan. 31-33*
  - atypical, *Jan. 32*
  - infection due to, *Jan. 18-19*
  - silicosis and, *Sept. 41*
  - tuberculosis due to, *Jan. 31-32*
- Mycobacterium tuberculosis*: and silicosis, *Sept. 43*
- Myocardium
  - fiber disarray, *Nov. 18*
  - fibrosis in ventricular septum, *Nov. 16*
  - scanning with <sup>201</sup>Tl in cardiomyopathy, *Nov. 55*
- Myositis, *Jan. 48*

## N

- Naloxone: effects of, *July 35*
- National Council on Radiation Protection and Measurements, *Mar. 82*
- Necrosis, kidney
  - papillary, *Feb. 66*
  - tubular (see Kidney, tubular necrosis)
- Necrotizing vasculitis:
  - classification of, *Oct. 9*
- Nephritis
  - interstitial, acute, *Feb. 50-55*
  - clinical presentation, *Feb. 53-54*
  - diagnosis, *Feb. 53-54*
  - drugs associated with, *Feb. 51*
  - pathogenesis, *Feb. 51-52*
  - pathology, *Feb. 51-52*
  - therapy, *Feb. 53-54*
  - lupus, clinical features of *Apr. 31*
- Nephropathy
  - amphetamine-associated, *Feb. 70*
  - analgesic-associated, *Feb. 62*

## Nephropathy (*cont.*)

- heroin-associated, *Feb.* 69–70
- lithium-associated, *Feb.* 68–69
- minimal-change
  - electron micrograph of, *Apr.* 40
  - nephrotic syndrome and, *Apr.* 39–43
- uric acid, *Feb.* 57–58
- Nephrotic syndrome, *Feb.* 70–78,
  - Apr.* 5–56
- albuminuria in, pathogenesis,
  - Feb.* 71–73
- amyloidosis causing, *Apr.* 24–27
- anticonvulsants and, *Feb.* 78
- cancer causing, *Apr.* 27–29
- captopril and, *Feb.* 78
- classification of, *Apr.* 20–22
- complications, life-threatening,
  - Apr.* 17–20
- diabetes causing, *Apr.* 22–24
- diagnosis, *Apr.* 49–53
- drug-induced, *Feb.* 70–78
- drugs and, *Apr.* 33–36
- edema formation in, mechanisms of, *Apr.* 11
- glomerulus in, *Apr.* 7–8
- hypercoagulability in, possible mechanisms, *Apr.* 19
- idiopathic, *Apr.* 36–49
  - clinical features of, *Apr.* 51
- glomerulonephritis and, membranoproliferative, *Apr.* 46–49
- glomerulopathy in, membranous, *Apr.* 36–39
- glomerulosclerosis and, focal, *Apr.* 43–46
- nephropathy and, minimal-change, *Apr.* 39–43
- renal histopathology resembling, *Apr.* 21
- lupus erythematosus causing, systemic, *Apr.* 29–33
- management, *Apr.* 49–53
- penicillamine and, *Feb.* 77–78
- protein deficiencies and, *Apr.* 13–14

## proteinuria in

- (*See also* Proteinuria, heavy)
- consequences of, *Apr.* 11
- renal failure and, *Apr.* 17
- secondary
  - causes of, *Apr.* 20
  - causes of, common, *Apr.* 22–33
- thromboembolism complicating,
  - Apr.* 17–20

## toxins and, *Apr.* 33–36

## tubule in, *Apr.* 7–8

## urine sediment in, *Apr.* 16

## vascular collapse and, *Apr.* 17

## Nephrotoxic

## kidney failure

## drug-induced, etiology, *Feb.*

26–47

## pathogenic pathways in, *Feb.*

19

## syndrome, drug-induced,

## pathogenesis, *Feb.* 74–76

## Nephrotoxicity

## aminoglycoside, risk factors in,

*Feb.* 29

## drug-induced, *Feb.* 8–81

## etiology, *Feb.* 9

## Neuroendocrine control: of

## prolactin secretion, *June*

13–16

## Neuromodulators, *July* 20

## Neurons: containing transmitter

## and peptide, *July* 21

## Neurotransmitters, *July* 20

## North American blastomycosis,

*Jan.* 30

## Nuclear

## imaging, *Mar.* 31–33

## Regulatory Commission, *Mar.*

79–82

## O

## Obesity: and opioids, *July* 37–39

## O'nyong-nyong virus, *May* 43–44

## Opiate(s)

## -induced analgesia, *July* 26

## receptors

## characterization of, *July* 9–12

- heterogeneity of,  
characterization methods,  
*July 9*  
roles of, possible physiologic,  
*July 23-32*
- Opioid(s)**  
ACTH and, *July 43*  
acupuncture and, *July 28-29*  
addiction and, *July 32-33*  
alcohol dependence and, *July 33*  
behavior and, *July 29-32*  
blood pressure and, *July 34-36*  
in brain, *July 13-14*  
in cerebrospinal fluid, *July 19*  
distribution of, *July 12-16*  
exercise and, *July 33-34*  
in extra-CNS tissues, *July 16*  
feeding and, *July 37-39*  
gonadotropins and, *July 41-42*  
obesity and, *July 37-39*  
pain and, *July 23-28*  
peptides  
action mechanisms, *July 19-22*  
terminology for, *July 4*  
in pituitary, *July 14-16*  
pituitary hormone secretion and,  
*July 39-45*  
prolactin and, *July 42*  
in syndromes, clinical, *July 44-45*  
temperature and, *July 36-37*  
vasopressin and, *July 43-44*
- Osteomyelitis, Jan. 16-18**  
acute, *Jan. 16*  
chronic, *Jan. 16-17*  
vertebral, *Jan. 17-18*
- Oxyntic gland area: of stomach,**  
schematic diagram, *Dec. 8*
- P**
- Pain**  
abdominal, *Oct. 18*  
opioids and, *July 23-28*
- Pancreas**  
imaging of, *Mar. 57-58*  
mass, *Mar. 61*  
diagnostic approach, *Mar. 60*  
Parainfluenza viruses 1-3, *May 42*  
Pelvimetry, *Mar. 63*  
Penicillamine: and nephrotic  
syndrome, *Feb. 77-78*  
Peptic (see Ulcer, peptic)  
Petechial exanthems, *May 17*  
Pharmacotherapy: of peptic ulcer,  
*Dec. 37-43*  
Phenacetin, *Feb. 65*  
Pheochromocytoma  
thyroid carcinoma and,  
medullary, *Aug. 20-22*  
treatment, *Aug. 21-22*  
Phonocardiography: in  
cardiomyopathy, *Nov. 25*  
Photomicrograph: electron, of  
normal glomerulus, *Apr. 40*  
Physical examination: in  
cardiomyopathy, *Nov. 23-29*  
Pitressin stimulation, *July 18*  
Pituitary  
hormone secretion and opioids,  
*July 39-45*  
-hypothalamic axis, activation  
of, *July 18*  
-hypothalamic-gonadal axis and  
prolactin, *June 24-26*  
opioids in, *July 14-16*
- Plaque**  
calcified, in asbestosis, *Sept. 26-27, 29*  
pleural, in asbestosis, *Sept. 11-13*  
calcified, *Sept. 29*
- Pleura in asbestosis (see Asbestosis, pleura in)**
- Pneumonitis: interstitial, Sept. 17**
- Polyarteritis nodosa, Oct. 37-41,**  
*Jan. 45-47*  
clinical involvement in, *Oct. 40*  
etiology, factors in, *Oct. 38*  
skin in, *Oct. 39*  
vasculitis in, *Oct. 15*
- Poly myositis-dermatomyositis, Oct. 34**
- Polymyxins: causing kidney failure, Feb. 39-40**

Pore size and charge: and glomerulus, *Apr. 8-9*  
 Postextrasystolic beat phenomenon, *Nov. 41*  
 Postmeningococcal arthritis, *Jan. 39-40*  
 Poststaphylococcal arthritis, *Jan. 39-40*  
 Pregnancy  
   after bromocriptine, *June 41*  
   radiation and, *Mar. 68-69*  
 Pressure recordings: from ventricle and femoral artery, *Nov. 38*  
 Prolactin  
   action  
     on breast, *June 24-26*  
     mechanism of, *June 24-26*  
   hypothalamic-pituitary-gonadal axis and, *June 24-26*  
   opioids and, *July 42*  
   secretion  
     neuroendocrine control of, *June 13-16*  
     regulation of, *June 14*  
     twenty-four-hour pattern, *June 8*  
 Prolactinoma  
   CT of, *June 37*  
   in hyperprolactinemia etiology, *June 20-23*  
   in men, treatment of, *June 45*  
   in women  
     bromocriptine in, *June 35-43*  
     surgery of, *June 34-35*  
     treatment, *June 33-43*  
 Pro-opiomelanocortin molecule peptide backbone, *July 7*  
 Prostaglandin inhibitors, *Feb. 11*  
 Prosthetic joint: infection of, *Jan. 9-12*  
 Protein  
   C-reactive, in SLA. *Jan. 49*  
   deficiencies, and nephrotic syndrome, *Apr. 13-14*  
   renal excretion of, *Apr. 7*  
 Proteinuria, heavy  
   arteriosclerosis and, accelerated, *Apr. 16-17*

complications of, life-threatening, *Apr. 17-20*  
 consequences of, common, *Apr. 9-17*  
 edema and, *Apr. 10-13*  
 hyperlipidemia and, *Apr. 14-15*  
 hypoalbuminemia and, *Apr. 9-10*  
 lipiduria and, *Apr. 14-15*  
 mechanisms of, *Apr. 7-9*  
 in nephrotic syndrome, *Apr. 11*  
 Pseudocyesis: and  
   hyperprolactinemia etiology, *June 20*  
 Psychosomatic theory: of duodenal ulcer, *Dec. 23*  
 Psychotherapy: in ulcer, guidelines for, *Dec. 25*  
 Public health aspects: of radiation, *Mar. 78-90*  
 Purpura  
   cephalexin causing, *Oct. 18*  
   Henoch-Schönlein, *Oct. 18, 20-23*  
   palpable, *Oct. 18*  
 Purpuric exanthems, *May 17*  
 Pyloric stenosis: in ulcer, *Dec. 51-53*  
 Pyomyositis, *Jan. 15-16*

## R

Radiation  
   background, *Mar. 11-13*  
   cancer induction and, *Mar. 41-47*  
   carcinogenic induction by, *Mar. 42-43*  
   cataracts and, *Mar. 40-41*  
   congenital effects of (in mammals), *Mar. 46*  
   contamination and, *Mar. 9*  
   dose, *Mar. 16-20*  
     average, to irradiated volume, *Mar. 19*  
     collective, *Mar. 19*  
     depth, *Mar. 18*  
     distributions, *Mar. 17-20*

- film-badge dose data, *Mar.* 85  
genetically significant, *Mar.*  
20, 74  
genetically significant, sources  
of, *Mar.* 48  
gonadal, *Mar.* 74  
integral, *Mar.* 19  
-limiting recommendations of  
NCRP, *Mar.* 83  
organ, *Mar.* 18  
organ, average, *Mar.* 18  
reduction by technology, *Mar.*  
69-71  
-risk curve, *Mar.* 37  
skin, *Mar.* 17  
skin, for abdominal imaging,  
*Mar.* 52  
from x-ray examination, *Mar.*  
19-20  
effects, *Mar.* 33-50  
environmental protection and,  
*Mar.* 88  
exposure, *Mar.* 16  
annual dose rates from  
significant sources, *Mar.*  
80-81  
entrance skin, *Mar.* 17-18  
reduction, estimated, *Mar.* 71  
fertility and, *Mar.* 40, 76  
fetus and, *Mar.* 44-47, 75  
genetic effects of, *Mar.* 47-50  
-induced aging, *Mar.* 39-40  
kinds of, *Mar.* 7-11  
levels, relative, *Mar.* 21-22  
gross comparison of, *Mar.* 22  
local governments and, *Mar.* 82  
pregnancy and, *Mar.* 68-69  
professional societies in, *Mar.* 84  
public health aspects of, *Mar.*  
78-90  
quantities, *Mar.* 16-21  
risk, *Mar.* 14-16  
of carcinogenesis, *Mar.* 36  
in diagnostic radiology, *Mar.*  
5-96  
-dose curve, *Mar.* 37  
to patient, *Mar.* 71-77  
probable maximal lifetime, for  
selected examinations, *Mar.*  
73  
somatic effects of, *Mar.* 39-41  
state governments and, *Mar.* 82  
units, *Mar.* 16-21  
utilization, *Mar.* 62-63  
workers, *Mar.* 84-87  
Radioactive materials, *Mar.* 89-90  
Radiocontrast agents: causing  
kidney failure, *Feb.* 43-46  
Radiography  
of amenorrhea, *June* 27-30  
in arthritis, infectious, *Jan.*  
24-25  
in cardiomyopathy, *Nov.* 32-36  
chest, in cardiomyopathy, *Nov.*  
32  
examination, *Mar.* 22-24, 50-69  
reported doses from, *Mar.* 25  
of galactorrhea, *June* 27-30  
of hyperprolactinemia, *June*  
27-30  
imaging procedures, *Mar.* 22-33  
radiation risks associated with,  
*Mar.* 5-96  
selection of patients for, *Mar.*  
50-69  
skull, *Mar.* 63-65  
in ulcer, peptic, *Dec.* 31-36  
uroradiography of renal  
papillary necrosis, *Feb.* 66  
Radiology: monument to Martyrs  
of, *Mar.* 39  
Radionuclides  
dose, *Mar.* 21  
internally administered, *Mar.*  
8-10  
Radiopharmaceuticals: and  
estimated radiation dose,  
*Mar.* 32  
Radiotherapy: long mean latencies  
after, *Mar.* 45  
Ranitidine: structure, *Dec.* 38  
Renal (see Kidney)  
Reoviruses, *May* 45-46  
Respiratory viruses, *May* 41-43  
exanthems, importance of, *May*  
42-43

Respiratory viruses (*cont.*)  
 syncytial, *May 42*  
 Retroperitoneal adenopathy, *Mar.*  
     51-54  
     diagnostic approach, *Mar.* 53  
 Rheumatic  
   disease  
     chronic infection, and disguise,  
       *Jan.* 45-47  
     joint fluid in, *Jan.* 23  
     problems misdiagnosed as  
       infection, *Jan.* 43-45  
     vasculitis and, *Oct.* 30-34  
     fever, *Jan.* 40-41  
 Rheumatoid  
   arthritis, *Oct.* 32-34  
     infection in, *Jan.* 47-48  
   vasculitis (*see* Vasculitis,  
     rheumatoid)  
 "Rheumatologic" cutaneous signs:  
     of infection, *Jan.* 19-20  
 Rhinoviruses, *May 42*  
 Roseola infantum, *May 46-48*  
 Ross River virus, *May 43-44*  
 Rubella, *Jan.* 29, *May 22-24*  
     in vaccine era, *May 28-29*

## S

Scanning  
   bone, in infectious arthritis, *Jan.*  
     25-26  
   heart, in cardiomyopathy, *Nov.*  
     54-57  
   myocardial with <sup>201</sup>Tl, in  
     cardiomyopathy, *Nov.* 55  
   nuclear, *Mar.* 31-33  
 Sepsis: and naloxone, *July 35*  
 Septic  
   bursitis, *Jan.* 13-14  
   joint, drainage of, *Jan.* 36  
 Sick cell, *Jan.* 42  
 Silica, *Sept.* 37-59  
   pathogenesis of fibrotic reaction  
     to, *Sept.* 37-40  
 Silicosis, *Sept.* 37  
   accelerated, *Sept.* 42, 52-53  
   acute, *Sept.* 42  
   biopsy of lung in, *Sept.* 42  
   case review, *Sept.* 45-59  
   as chronic disease, *Sept.* 41  
   classification, *Sept.* 42  
     of I.L.O./U.C., *Sept.* 41-42  
   collagen vascular disease and,  
     *Sept.* 43  
   diagnosis, *Sept.* 40-41  
   lung insufficiency in, *Sept.* 43  
   lymph node calcification in, *Sept.*  
     49  
   mycobacterial infection and,  
     *Sept.* 41  
   *Mycobacterium tuberculosis* and,  
     *Sept.* 43  
   nodule of, *Sept.* 42, 47  
   smoking and, *Sept.* 43  
   therapy as ineffective, *Sept.* 43  
   Sindbis virus, *May 43-44*  
 Skin  
   dose, radiation, *Mar.* 17  
   for abdominal imaging, *Mar.*  
     52  
   exposure, entrance, and  
     radiation, *Mar.* 17-18  
   findings in enteroviral  
     infections, *May 32-33*  
   manifestations of viral  
     exanthems, *May 7-11*  
   polyarteritis nodosa in, *Oct.* 39  
   signs of infection,  
     "rheumatologic," *Jan.* 19-20  
   vasculitis, *Oct.* 7-46  
 Skull radiography, *Mar.* 63-65  
 Smoking  
   asbestos exposure and, *Sept.* 22  
   peptic ulcer and, *Dec.* 16-17  
   silicosis and, *Sept.* 43  
 Socioeconomic status: in peptic  
   ulcer, *Dec.* 19  
 Spondyloarthropathy: B27, *Jan.* 47  
 Sporotrichosis, *Jan.* 30  
 Sputum  
   asbestos body in, *Sept.* 13  
   cytology in smoking and  
     asbestos exposure, *Sept.* 22  
 State governments: and radiation,  
   *Mar.* 82  
 Stenosis: pyloric, and ulcer, *Dec.*  
   51-53

Stevens-Johnson syndrome, *May*  
18  
Stomach  
(See also Gastrointestinal)  
acid, and duodenal ulcer, *Dec.* 27  
acidity during 24-hour period,  
*Dec.* 40  
function abnormalities in gastric  
ulcer, *Dec.* 28-30  
outlet obstruction in ulcer, *Dec.*  
51-53  
oxyntic gland area of, schematic  
diagram, *Dec.* 8  
ulcer (see Ulcer, gastric)  
Streptococcal bacteremia: and  
naloxone, *July* 35  
Stress-induced analgesia, *July* 26  
Sudden death: in cardiomyopathy,  
predictors of, *Nov.* 65  
Sulfonamides: and kidney failure,  
*Feb.* 57  
Synovial  
fluid, microbial antigen in, *Jan.*  
47-48  
joint infection, *Jan.* 8-9  
Synovitis: of hip, transient, *Jan.*  
41  
Syphilitic arthritis, *Jan.* 34

## T

Temperature: and opioids, *July*  
36-37  
Tenditis: calcific, *Jan.* 43-44  
Tenosynovitis: bacteremic, *Jan.*  
12-13  
Tenosynovium infection, *Jan.* 12  
focal, *Jan.* 12  
Tetracyclines: causing kidney  
failure, *Feb.* 39-40  
Thallium-201 myocardial  
scanning: in  
cardiomyopathy, *Nov.* 55  
Theory: psychosomatic, of  
duodenal ulcer, *Dec.* 23  
Thromboembolism: complicating  
nephrotic syndrome, *Apr.*  
17-20  
Thyroid

anatomy, normal, *Aug.* 29-30  
carcinoma (see Carcinoma,  
thyroid)  
embryology, *Aug.* 29-30  
Tomography, computed  
in arthritis, infectious, *Jan.*  
25-26  
discussion of, *Mar.* 28-30  
dose distributions from, *Mar.* 29  
of microadenoma, *June* 29  
of prolactinoma, *June* 37  
Toxic concentrations: of  
aminoglycosides, *Feb.* 31  
Toxins: and nephrotic syndrome,  
*Apr.* 33-36  
Toxoplasmosis, *Jan.* 48  
Tuberculosis: mycobacterium, *Jan.*  
31-32  
Tubule, kidney  
(See also Kidney, tubular)  
contributions in nephrotic  
syndrome, *Apr.* 7-8  
Tubulointerstitial disease, drug-  
induced, *Feb.* 61-68  
clinical features, *Feb.* 64-67  
diagnosis, *Feb.* 64-67  
pathogenesis, *Feb.* 62-64  
pathology, *Feb.* 62-64  
treatment, *Feb.* 64-67

## U

Ulcer  
antrum, on lesser curve, *Dec.* 35  
duodenal  
clinical trials in, *Dec.* 44-46  
crater of, *Dec.* 32  
gastric acid and, *Dec.* 27  
gastrointestinal function  
abnormalities in, *Dec.* 24-28  
physiologic defects in, *Dec.* 26  
psychosomatic theory of, *Dec.*  
23  
gastric  
gastric function abnormalities  
in, *Dec.* 28-30  
physiologic defects in, *Dec.* 29  
in typical location, *Dec.* 33

Ulcer (*cont.*)

- gastric outlet obstruction in,  
*Dec.* 51-53
- heredity and, *Dec.* 11-14
- hospitalizations for, *Dec.* 10
- peptic, *Dec.* 6-58
  - alcohol and, *Dec.* 16
  - associated diseases and, *Dec.* 19-21
  - complications, *Dec.* 47-53
  - diagnosis, differential, *Dec.* 36
  - diet and, *Dec.* 14-15
  - drugs and, *Dec.* 17-19
  - economics of, *Dec.* 8-11
  - emotional factors in, *Dec.* 21-24
  - endoscopy of, *Dec.* 31-36
  - environmental factors in, *Dec.* 19
  - epidemiology of, *Dec.* 8-11
  - gastrointestinal hemorrhage in, upper, *Dec.* 48-50
  - genetic syndromes with, *Dec.* 12-13
  - outlook, long-term, *Dec.* 46-47
  - penetration in, *Dec.* 50-51
  - perforation in, *Dec.* 50-51
  - pharmacotherapy of, *Dec.* 37-43
  - physical examination in, *Dec.* 36
  - radiography of, *Dec.* 31-36
  - smoking and, *Dec.* 16-17
  - socioeconomic status and, *Dec.* 19
  - surgery in, *Dec.* 53-55
  - symptoms of, *Dec.* 30-31
  - therapy of, medical, *Dec.* 36-47
  - psychotherapy in, guidelines for, *Dec.* 25
  - remission during cimetidine, *Dec.* 45
  - in vasculitis, *Oct.* 19
- Ulcerative exanthems, *May* 18
- Ultrasonic generators, *Mar.* 10-11
- imaging, *Mar.* 30
- pulses and pulse echoes,

- generation of, *Mar.* 11
- Ultrasound, *Mar.* 76-77
- Uric acid nephropathy, *Feb.* 57-58
- Urinary indices: in kidney failure, *Feb.* 25
- Urine sediment: in nephrotic syndrome, *Apr.* 16
- Uroradiography: of renal papillary necrosis, *Feb.* 66
- Urticarial exanthems, *May* 17-18
- vasculitis, *Oct.* 23-27

V

- Vaccine era
  - measles in, *May* 25-28
  - rubella in, *May* 28-29
- Varicella, *May* 24-25
- Vascular (*see* Vessels)
- Vasculitis
  - classification, *Oct.* 8-10
  - clinical manifestations, *Oct.* 17-19
  - corticosteroids in, indications for, *Oct.* 44
  - cutaneous, *Oct.* 7-46
  - diagnosis, differential, *Oct.* 41
  - etiology, *Oct.* 10-14
  - evaluation, *Oct.* 41-42
  - granulomatous, *Oct.* 34-37
  - hypocomplementemic, *Oct.* 23-27
  - leukocytoclastic, *Oct.* 14, 16, 19-30, *Jan.* 20
  - systemic diseases associated with, *Oct.* 21
  - necrotizing, classification of, *Oct.* 9
  - pathogenesis, *Oct.* 10-14
  - theoretical, schematic representation of, *Oct.* 13
  - pathology, *Oct.* 14-17
  - in polyarteritis nodosa, *Oct.* 15
  - rheumatic diseases and, *Oct.* 30-34
  - rheumatoid, *Oct.* 32
  - digital infarction in, *Oct.* 33

- hemorrhagic lesions in, *Oct.* 33
- syndromes of, etiologic factors in, *Oct.* 11
- systemic, classification of, *Oct.* 10
- systemic disease and, *Oct.* 7-46
- systemic involvement in, *Oct.* 20
- therapy of, *Oct.* 43-45
- ulcer in, *Oct.* 19
- urticarial, *Oct.* 23-27
- Vasoconstrictor hormones, *Feb.* 12
- Vasodilator hormones, *Feb.* 12
- Vasopressin: and opiods, *July* 43-44
- Venereal infections, *Jan.* 39
- Ventricle
  - peak filling rate, *Nov.* 57
  - pressure recordings from, *Nov.* 38-39
  - septum, myocardial fibrosis in, *Nov.* 16
- Ventriculography, *Nov.* 35
- Vertebra: osteomyelitis, *Jan.* 17-18
- Vesicular exanthems, *May* 16-17
- Vessels
  - collapse, and nephrotic syndrome, *Apr.* 17
  - disease, collagen (*see* Collagen vascular disease)
  - large, disease, *Oct.* 41
- Virus(es)
  - adenoviral infections, *May* 41
  - arboviruses, *Jan.* 29
  - arthritis due to, *Jan.* 28-29
  - associated with cutaneous manifestations, *May* 7-11
  - chikungunya, *May* 43-44
  - Colorado tick fever, *May* 43
  - Coxsackievirus (*see* Coxsackievirus)
  - cytomegalovirus, *May* 45
  - dengue, *May* 44
  - echovirus (*see* Echovirus)
  - enteroviruses (*see* Enteroviruses)
  - Epstein-Barr, *May* 45
  - exanthems (*see* Exanthems, viral)
  - geographically important, *May* 43-45
  - hepatitis B, *Jan.* 28, *May* 46
  - illness of presumed viral etiology, *May* 46-48
  - infection due to, *Jan.* 18
  - influenza A and B, *May* 42
  - kunjin, *May* 44
  - lassa, *May* 44
  - Marburg, *May* 45
  - mumps, *May* 46
  - o'nyong-nyong, *May* 43-44
  - parainfluenza, 1-3, *May* 42
  - reoviruses, *May* 45-46
  - respiratory (*see* Respiratory viruses)
  - rhinovirus, *May* 42
  - Ross River, *May* 43-44
  - Sindbis, *May* 43-44
  - specific, and specific disease, *May* 19-29
  - West Nile, *May* 44

## W

- Wegener's granulomatosis, *Oct.* 36-37
- West Nile virus, *May* 44

## X

- X-ray
  - examination, radiation dose from, *Mar.* 19-20
  - generators, *Mar.* 7-8
  - utilization, *Mar.* 62-63